Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- PMID: 33596348
- DOI: 10.1056/NEJMc2036242
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Comment in
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.N Engl J Med. 2021 Apr 22;384(16):1578. doi: 10.1056/NEJMc2036242. Epub 2021 Feb 17. N Engl J Med. 2021. PMID: 33596351 No abstract available.
Comment on
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. N Engl J Med. 2020. PMID: 33301246 Free PMC article. Clinical Trial.
Similar articles
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.N Engl J Med. 2021 Apr 22;384(16):1578. doi: 10.1056/NEJMc2036242. Epub 2021 Feb 17. N Engl J Med. 2021. PMID: 33596351 No abstract available.
-
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.Ann Intern Med. 2021 Feb;174(2):JC15. doi: 10.7326/ACPJ202102160-015. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524290
-
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.N Engl J Med. 2021 May 20;384(20):1968-1970. doi: 10.1056/NEJMc2104281. Epub 2021 Apr 21. N Engl J Med. 2021. PMID: 33882226 No abstract available.
-
Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.Front Immunol. 2021 Mar 12;12:657711. doi: 10.3389/fimmu.2021.657711. eCollection 2021. Front Immunol. 2021. PMID: 33777055 Free PMC article. Review.
-
[SARS-CoV-2 vaccines].Ugeskr Laeger. 2021 Mar 8;183(10):V01210052. Ugeskr Laeger. 2021. PMID: 33734065 Review. Danish.
Cited by
-
The effect of COVID-19 vaccination on symptomatic infection and related symptoms among preterm-born children aged 3-7 years in China.Sci Rep. 2024 Oct 25;14(1):25384. doi: 10.1038/s41598-024-76609-1. Sci Rep. 2024. PMID: 39455727 Free PMC article.
-
Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium.J Nanobiotechnology. 2024 Oct 12;22(1):620. doi: 10.1186/s12951-024-02892-9. J Nanobiotechnology. 2024. PMID: 39396002 Free PMC article. Review.
-
Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study.Viruses. 2024 Sep 18;16(9):1481. doi: 10.3390/v16091481. Viruses. 2024. PMID: 39339957 Free PMC article.
-
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends.Biomark Res. 2024 Aug 31;12(1):93. doi: 10.1186/s40364-024-00644-3. Biomark Res. 2024. PMID: 39217377 Free PMC article. Review.
-
Comprehensive Analysis of SARS-CoV-2 Dynamics in Bangladesh: Infection Trends and Variants (2020-2023).Viruses. 2024 Aug 7;16(8):1263. doi: 10.3390/v16081263. Viruses. 2024. PMID: 39205237 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical